Account

Search results for: vpag

VPAG for manufacturers: boom or gloom for UK launc...

We discuss the 2024 VPAG agreement, how it differs from the previous VPAS and whether this will impa...

Read more
VPAS is dead, long live VPAG: the impact of the UK...

Webinar: Discussions on the new Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (...

Read more
If You’re a Market Access Lead in 2026: How to N...

In 2026, U.S. policy shifts will link domestic US prices to internatio...

Read more
MFN Drug Pricing Proposal: What It Could Mean for ...

Negotiations between the Trump administration and pharmaceutical companies on lowering U.S...

Read more
ISPOR Europe 2024: Implications of Indication Expa...

We examine the impact of indication expansions on pricing and reimbursement strategies across EU4 an...

Read more
World EPA Congress 2024: Implications of indicatio...

The study explores the complexities of pricing and reimbursement for multi-indication products in th...

Read more
Is the attractiveness of launch in the UK changing...

This expert article focusses on the new proportionate approach, and the international recognition pr...

Read more
What are the 5 Pricing & Market Access trends...

Our experts provide an overview of the five key trends that could shape the pricing and market acces...

Read more
Reflecting on the Pricing & Market Access tre...

Back in January this year, we summarised the key trends our market access experts believed would dom...

Read more
New rebate percentages in the Statutory Scheme are...

The statutory scheme has been updated with new percentages for 2024-2026, and has received backlash ...

Read more
Older

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch